Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis

被引：8
|
作者：
Doshi, Bhavya S. [1 ,2 ]
Witmer, Char M. [1 ,2 ]
机构：
[1] Childrens Hosp Philadelphia, Div Hematol, 3501 Civ Ctr Blvd,CTRB 5024, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA
来源：
HAEMOPHILIA | 2021年 / 27卷 / 04期
关键词：
emicizumab; haemophilia A; immune tolerance; inhibitor; recurrence; IMMUNE TOLERANCE;
D O I：
10.1111/hae.14311
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E551 / E553
页数：3
相关论文
共 50 条
  • [31] Successful Response to Rituximab, Cyclophosphamide and Corticosteroids as First Line Therapy in a Post-Partum Patient with Very High-Titre Acquired Factor VIII Inhibitor
    Malato, A.
    Acquaviva, F.
    Felice, R.
    Magrin, S.
    Lo Coco, L.
    Napolitano, M.
    Fabbiano, F.
    HAEMOPHILIA, 2016, 22 : 90 - 91
  • [32] Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea
    Lee, Hankil
    Cho, Hyeonseok
    Han, Jung Woo
    Kim, Ah-Young
    Park, Seonyoung
    Lee, Minjun
    Cho, Sunghwa
    Baik, Deborah
    Kang, Hye-Young
    HAEMOPHILIA, 2021, 27 (01) : E12 - E21
  • [33] High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis
    Messori, Andrea
    Peyvandi, Flora
    Trippoli, Sabrina
    Palla, Roberta
    Rosendaal, Frits R.
    Mannucci, Pier Mannuccio
    BLOOD TRANSFUSION, 2018, 16 (02) : 215 - 220
  • [34] A low-dose immune tolerance induction (ITI) protocol incorporating immunosuppressive agents in haemophilia A children with high-titre factor VIII inhibitor and poor-ITI prognostic risk
    Li, Zekun
    Chen, Zhenping
    Cheng, Xiaoling
    Liu, Guoqing
    Wu, Xinyi
    Li, Gang
    Zhen, Yingzi
    Cai, Siyu
    Poon, Man-Chiu
    Wu, Runhui
    HAEMOPHILIA, 2021, 27 (04) : E469 - E472
  • [35] Emicizumab prophylaxis overcomes factor VIII inhibitors in Hemophilia A
    Shima, Midori
    JOURNAL OF PEDIATRICS, 2017, 190 : 289 - 289
  • [36] Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy
    Field, J. J.
    Fenske, T. S.
    Blinder, M. A.
    HAEMOPHILIA, 2007, 13 (01) : 46 - 50
  • [37] Acquired high titre Factor VIII inhibitor with underlying polyarteritis nodosa
    Snowden, JA
    Hutchings, M
    Spearing, R
    Patton, WN
    PATHOLOGY, 1997, 29 (02) : 221 - 223
  • [38] Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors
    Kurth, M. A. H.
    Dimichele, D.
    Sexauer, C.
    Sanders, J. M.
    Torres, M.
    Zappa, S. C.
    Ragni, M.
    Leonard, N.
    HAEMOPHILIA, 2008, 14 (01) : 50 - 55
  • [39] Major surgery in a patient with Haemophilia A with high responder inhibitor (INH) on Emicizumab (Emi)
    Brodard, J.
    Quarroz, C.
    Pavicic, M.
    Baumgartner, D.
    Sommerhalder, R.
    Siebenrock, K.
    Angelillo-Scherrer, A.
    Hovinga, J. A. Kremer
    SWISS MEDICAL WEEKLY, 2019, 149 : 35S - 35S
  • [40] Successful long-term treatment with porcine factor VIII of a patient with haemophilia A and an inhibitor to factor VIII
    Vyas, P
    Pasi, KJ
    Lee, CA
    HAEMOPHILIA, 1996, 2 (04) : 240 - 243
12345